title: Adefovir-induced Stevens-Johnson syndrome and toxic epidermal necrolysis overlap syndrome.
abstract: An increasing number of patients with chronic hepatitis B infection are being treated with the newly licensed drug, adefovir. It is an acyclic nucleoside phosphonate that is relatively safe in the dosage generally used for chronic hepatitis B. Serious adverse cutaneous drug reactions like Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) following adefovir use have not been reported. We report a case of adefovir-induced SJS and TEN overlap syndrome in a patient with chronic hepatitis B infection.
authors.affiliation: Nil Ratan Sircar Medical College, Department of Medicine, 138 AJC Bose Road, Kolkata 700014, West Bengal, India. drpartha73@hotmail.com
authors.forename: P
authors.initials: P
authors.lastname: Chattopadhyay
authors.forename: N
authors.initials: N
authors.lastname: Sarma
mesh_terms: D000225:Adenine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001706:Biopsy; D004817:Epidermis / Q000648:ultrastructure; D005500:Follow-Up Studies; D019694:Hepatitis B, Chronic / Q000188:drug therapy*; D006801:Humans; D007166:Immunosuppressive Agents; D008297:Male; D008875:Middle Aged; D063065:Organophosphonates / Q000009:adverse effects* / Q000627:therapeutic use; D010784:Photomicrography; D013262:Stevens-Johnson Syndrome / Q000139:chemically induced* / Q000175:diagnosis / Q000209:etiology*
chemical_list: D000998:Antiviral Agents; D007166:Immunosuppressive Agents; D063065:Organophosphonates; C053001:adefovir; D000225:Adenine